Amyloidosis Clinical Trials
Here are the 6 most popular medical studies for amyloidosis
Proteasome Inhibitor
Ixazomib + Cyclophosphamide + Dexamethasone for Multiple Myeloma
This trial is testing cyclophosphamide given with ixazomib citrate and dexamethasone to see what effects, good and bad, it has in treating patients with previously untreated multiple myeloma or light chain amyloidosis.
Popular filter options for amyloidosis trials
AL Amyloidosis Clinical Trials
View 44 AL Amyloidosis medical studies.
Monoclonal Antibodies
Daratumumab Combination Therapy for Amyloidosis
This trial is testing a new cancer treatment to see if it is safe for people with heart problems. The new treatment is a combination of drugs, and the trial will also look at how well it works in people of different racial and ethnic backgrounds.
Small Molecule
APG-2575 Combinations for Multiple Myeloma
This trial is testing a new cancer drug, APG-2575, to see if it is safe and effective in patients with multiple myeloma who have relapsed or are refractory to other treatments. The study will start with two arms, both of which are independent.
ATTR Clinical Trials
View 37 ATTR medical studies.
Monoclonal Antibodies
Daratumumab Combination Therapy for Amyloidosis
This trial is testing a new cancer treatment to see if it is safe for people with heart problems. The new treatment is a combination of drugs, and the trial will also look at how well it works in people of different racial and ethnic backgrounds.
Small Molecule
APG-2575 Combinations for Multiple Myeloma
This trial is testing a new cancer drug, APG-2575, to see if it is safe and effective in patients with multiple myeloma who have relapsed or are refractory to other treatments. The study will start with two arms, both of which are independent.
TTR Positive Clinical Trials
View 6 TTR positive medical studies.
RNAi Therapeutics
Vutrisiran vs Patisiran for Amyloidosis
This trial is studying vutrisiran, which is given as a shot under the skin, to see how well it works compared to patisiran, which is given as a drip into a vein, for people with hereditary ATTR amyloidosis. People will get vutrisiran or patisiran once every 3 months or 3 weeks, respectively, for 18 months. The trial will use the placebo arm of the APOLLO study as an external comparator for the primary and most other efficacy endpoints during the 18 Month Treatment Period. Following the 18 Month Treatment Period, all participants will be randomized to receive
Molecular Imaging Probe
[68Ga]CBP8 PET/MRI Imaging for Cardiac Amyloidosis
This trial will measure if a PET/MRI probe can detect heart fibrosis in people with cardiac amyloidosis. It will also compare the PET/MRI probe with standard MRI measures in people with and without heart disease.
Phase 3 Amyloidosis Clinical Trials
View 71 phase 3 amyloidosis medical studies.
RNAi Therapeutics
Vutrisiran vs Patisiran for Amyloidosis
This trial is studying vutrisiran, which is given as a shot under the skin, to see how well it works compared to patisiran, which is given as a drip into a vein, for people with hereditary ATTR amyloidosis. People will get vutrisiran or patisiran once every 3 months or 3 weeks, respectively, for 18 months. The trial will use the placebo arm of the APOLLO study as an external comparator for the primary and most other efficacy endpoints during the 18 Month Treatment Period. Following the 18 Month Treatment Period, all participants will be randomized to receive
Monoclonal Antibodies
CAEL-101 for Amyloidosis
This trial is testing a new treatment for AL amyloidosis, which is a disease where abnormal proteins misfold and create free light chains that build up in organs. The new treatment, CAEL-101, is a monoclonal antibody that removes AL amyloid deposits from tissues and organs. The trial will test whether CAEL-101 improves overall survival and is safe and well tolerated in patients with stage IIIb AL amyloidosis.
Amyloidosis Clinical Trials With No Placebo
View 71 amyloidosis medical studies that do not have a placebo group.
Monoclonal Antibodies
Daratumumab Combination Therapy for Amyloidosis
This trial is testing a new cancer treatment to see if it is safe for people with heart problems. The new treatment is a combination of drugs, and the trial will also look at how well it works in people of different racial and ethnic backgrounds.
Small Molecule
APG-2575 Combinations for Multiple Myeloma
This trial is testing a new cancer drug, APG-2575, to see if it is safe and effective in patients with multiple myeloma who have relapsed or are refractory to other treatments. The study will start with two arms, both of which are independent.
View More Amyloidosis Trials
See another 44 medical studies focused on amyloidosis.
Frequently Asked Questions
Introduction to amyloidosis
What are the top hospitals conducting amyloidosis research?
In the realm of medical research, clinical trials are vital for advancing our understanding and treatment options for various conditions. When it comes to amyloidosis, a rare disease characterized by the build-up of abnormal proteins in organs and tissues, several top hospitals are leading the way. In Portland, Oregon Health & Science University stands out with eight ongoing amyloidosis trials and a cumulative total of 15 studies dedicated to this condition. Their first recorded trial took place in 2013, demonstrating their relatively recent but impactful involvement in amyloidosis research.
Meanwhile, Brigham and Women's Hospital in Boston has been actively contributing to the field as well. With seven current amyloidosis trials and a history that includes 12 conducted studies since their first trial in 2013, they continue to make strides towards better understanding this complex disease.
Further east at Detroit's Karmanos Cancer Institute, researchers are diligently conducting six active clinical trials focused on amyloidosis. Since initiating their inaugural study in 2012, they have accumulated valuable knowledge from a total of 13 past investigations.
Washington University School of Medicine located in Saint Louis is also playing its part with six ongoing amyloidosis trials. Having embarked on their first ever trial back in 2008 on this subject matter itself; over the years accumulating eleven experiments which aids significantly developing credible resources for patients suffering from such unusual ailments
At Dana-Farber Cancer Institute again situated within Boston’s vibrant medical community, five active clinical trials centered around treating or managing amyloidosis are being carried out presently along with an additional seven previously held investigations since pioneering into this field dating all the way back until1996 thus serving as an essential resource for both doctors and patients alike seeking promising solutions against dreading ailment like Amyloidsis
These top hospitals' dedication to expanding our knowledge base through rigorous research serves not only those currently affected by amyloidosis but builds foundations for future advancements that might benefit countless patients worldwide. Each trial, no matter how small it may seem, contributes to the greater body of knowledge that brings us closer to effective treatments and better quality of life for those living with amyloidosis.
Which are the best cities for amyloidosis clinical trials?
When it comes to amyloidosis clinical trials, several cities emerge as leading centers of research and innovation. Boston, Massachusetts takes the lead with 45 active trials focused on promising treatments like CAEL-101, Daratumumab, and Eplontersen. New york City follows closely behind with 36 ongoing studies exploring similar therapies. Rochester, Minnesota is also a prominent city in this field with 22 active trials investigating treatment options such as CAEL-101 and Tafamidis. Additionally, Portland, Oregon shows promise with 19 active trials examining Eplontersen, CAEL-101, and more. Lastly, Detroit Michigan also plays a significant role in these clinical trials with its participation in 16 studies that explore potential treatments for amyloidosis like CAEL-101 and Daratumumab.
Which are the top treatments for amyloidosis being explored in clinical trials?
Exciting advancements in clinical trials offer hope for the treatment of amyloidosis. Among the top contenders are CAEL-101, displaying promise in three active and three all-time trials since its introduction in 2020. Eplontersen is also gaining attention, with three ongoing trials and four total studies dedicated to amyloidosis since 2020. Additionally, daratumumab has shown potential through two active and eleven all-time trials since 2016. Another promising option is ixazomib, which is being tested in two current and six all-time amyloidosis trials after its listing in 2011. Finally, isatuximab rounds out the list with two active and four overall trials conducted since its debut in 2018—each trial bringing us closer to finding effective treatments for this challenging condition.
What are the most recent clinical trials for amyloidosis?
Exciting advances are being made in the field of amyloidosis, as recent clinical trials offer hope for improved treatment options. One notable study is investigating an on-off sequence approach to managing amyloidosis. This innovative strategy aims to optimize patient outcomes by carefully timing treatment regimens. Additionally, a trial examining the efficacy of AMDX-2011P 50 mg holds promise for individuals affected by this condition. Another investigation focuses on venetoclax, exploring its potential benefits in treating amyloidosis patients. Furthermore, Phase 2 research evaluates the effectiveness of daratumumab cycles as part of Arm I therapy for amyloidosis management. Lastly, a study investigates dosimetry estimation and biodistribution patterns using 99mTc-p5+14 in healthy subjects with amyloidosis—an essential step towards improving diagnosis and monitoring techniques. These ongoing studies offer considerable optimism for those battling against amyloidosis and may provide vital breakthroughs in future treatments.
What amyloidosis clinical trials were recently completed?
Recent advancements in amyloidosis research have seen the completion of several notable clinical trials. In March 2022, a trial sponsored by Columbia University investigated the potential of Empagliflozin in addressing this complex condition. Another significant study, conducted by Ionis Pharmaceuticals, Inc., concluded their investigation into Eplontersen in January 2020. Additionally, Eidos Therapeutics completed a trial for acoramidis back in March 2019. These collective efforts highlight the ongoing dedication to finding effective treatments and management strategies for amyloidosis patients.